NEW YORK (GenomeWeb) – WuXi Nextcode and N-of-One have signed a global agreement under which N-of-One will provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation.
N-of-One's clinical interpretation service provides scientific and clinical evidence on the unique mutation profiles of patients' tumors including therapeutic strategies that are relevant for each patient. WuXi Nextcode provides sequencing and analysis resources that enable researchers and clinicians to use genomics information to better diagnose disease and improve treatments. Its database and informatics infrastructure support precision medicine efforts in the US, the Middle East, and elsewhere.
The agreement will allow the companies to collaborate on WuXi NextCODE's work with the UK 100K Genomes Project as well as provide tailored offerings for other geographies moving forward, N-of-One said.
"We are very pleased to be able to offer N-of-One solutions to our cancer diagnostics partners," Hannes Smarason, co-founder, president, and COO of WuXi Nextcode, said in a statement. "N-of-One provides the latest scientific and clinical evidence to enable clinicians to find the treatments best suited to each patient."
"Our objective is to continue to provide high-quality, patient-specific clinical interpretation evidence at a cost-effective price and through our partnership with WuXi [Nextcode] to extend our reach globally," Chris Cournoyer, N-of-One's CEO, added.
Financial and other terms of the agreement are not disclosed.